Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXYCONTIN vs XDEMVY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression.
XDEMVY (lotilaner ophthalmic solution) is a gamma-aminobutyric acid (GABA)-gated chloride channel antagonist. It inhibits the GABA-gated chloride channels in Demodex mites, leading to paralysis and death of the mites.
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate,Off-label: Treatment of opioid dependence (as part of substitution therapy)
Treatment of Demodex blepharitis
10 mg orally every 12 hours; titrate based on pain severity and prior opioid exposure.
1 drop in each eye once daily in the evening for 6 weeks.
4.5-5.0 hours (immediate-release); controlled-release OXYCONTIN has an apparent half-life of 4.5-8.7 hours. Terminal half-life is ~3.5-4 hours for immediate-release, reflecting context-sensitive elimination.
Terminal elimination half-life of approximately 4-6 hours; clinically, steady-state is reached within 24-36 hours.
Oxycodone is metabolized primarily via CYP3A4 to noroxycodone (major metabolite) and via CYP2D6 to oxymorphone (minor metabolite). Both metabolites are active, with oxymorphone having higher potency. Oxycodone and its metabolites are conjugated and excreted in urine.
Lotilaner is metabolized via cytochrome P450 (CYP) enzymes, primarily CYP3A4, and to a lesser extent CYP2C9 and CYP2C19.
Primarily renal (90% as metabolites, 10% unchanged). Also biliary/fecal (10%).
Primary renal excretion as unchanged drug and metabolites; ~70% in urine. Biliary/fecal excretion accounts for ~25%.
38-45%, primarily bound to albumin.
Approximately 90% bound to serum albumin and alpha-1-acid glycoprotein.
2.6-3.0 L/kg. Extensive tissue distribution, high Vd indicates penetration into peripheral tissues.
Volume of distribution is 0.35 L/kg, indicating limited extravascular distribution.
Oral immediate-release: 60-87% (first-pass metabolism). Oral extended-release (Oxy Contin): 60-87% (similar). Intravenous: 100%.
Oral bioavailability is approximately 85%; food may delay absorption but does not affect extent.
Cr Cl 30-60 m L/min: reduce dose by 25%; Cr Cl <30 m L/min: reduce dose by 50% and administer every 12 hours; hemodialysis: avoid use.
No dosage adjustment is recommended for patients with renal impairment.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
No dosage adjustment is recommended for patients with hepatic impairment.
Not approved for pediatric patients <18 years; for children ≥11 years (opioid-tolerant): 0.2 mg/kg orally every 12 hours, titrate; maximum single dose 10 mg.
Safety and efficacy have not been established in pediatric patients.
Initiate at 5 mg orally every 12 hours; titrate cautiously; monitor for respiratory depression and constipation.
No dosage adjustment is recommended based on age; clinical studies included patients ≥65 years, and no overall differences in safety or efficacy were observed.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS
None
Addiction, abuse, and misuse: Oxy Contin exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing, and monitor all patients regularly for the development of these behaviors or conditions.,Life-threatening respiratory depression: Serious, life-threatening, or fatal respiratory depression may occur. Monitor for respiratory depression, especially during initiation of therapy or following a dose increase. Instruct patients to swallow tablets whole; crushing, chewing, or dissolving can cause rapid release and absorption of a potentially fatal dose.,Accidental ingestion: Accidental ingestion of even one dose of Oxy Contin, especially by children, can result in a fatal overdose of oxycodone.,Neonatal opioid withdrawal syndrome: Prolonged use of Oxy Contin during pregnancy can result in withdrawal in the neonate. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal in adults, may be life-threatening if not recognized and treated.,Risks from concomitant use with benzodiazepines or other CNS depressants: Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate.
Contains preservative benzalkonium chloride, which may cause eye irritation and is adsorbable by soft contact lenses. Patients should remove contact lenses prior to administration and wait at least 15 minutes before reinserting.,Use with caution in patients with known hypersensitivity to any component of the product.,Not for injection. For topical ophthalmic use only.
Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Hypersensitivity (e.g., anaphylaxis) to oxycodone or any other components of the product
Hypersensitivity to lotilaner or any component of the formulation.
Avoid alcohol, which can increase oxycodone absorption and central nervous system depression. Grapefruit juice may alter oxycodone metabolism; limit or avoid consumption. No specific food restrictions, but high-fat meals may slow absorption slightly; take with or without food consistently.
No clinically significant food interactions reported.
FDA Pregnancy Category C prior to 2020; no adequate studies in pregnant women. First trimester: Limited data suggest possible increased risk of neural tube defects (1.8-fold) and oral clefts (1.5-fold) with opioid use, but confounded by underlying conditions. Second and third trimesters: Chronic use may cause fetal opioid dependence and neonatal abstinence syndrome (NAS); maternal withdrawal may precipitate preterm labor. Avoid prolonged use near term due to risk of neonatal respiratory depression.
No adequate and well-controlled studies in pregnant women. In animal reproduction studies, no teratogenic effects were observed at exposures up to 5 times the human exposure at the recommended ophthalmic dose. Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus.
Oxycodone is excreted into breast milk; relative infant dose is approximately 2.7–8.8% of maternal weight-adjusted dose. M/P ratio unknown. Monitor infant for sedation, respiratory depression, and poor feeding. American Academy of Pediatrics considers oxycodone compatible with breastfeeding with caution; avoid rapid accumulation in mothers with impaired metabolism (CYP2D6 poor metabolizers).
Unknown if excreted in human milk. No data on M/P ratio. Caution advised; consider developmental benefits of breastfeeding vs potential drug exposure.
Pregnancy increases oxycodone clearance by 1.3- to 2.5-fold due to enhanced hepatic metabolism (CYP3A4 and CYP2D6 induction) and increased renal blood flow. Dose adjustments may be necessary to maintain analgesia; clinical monitoring for pain control and withdrawal symptoms is essential. Titrate to effect; avoid abrupt discontinuation. Postpartum clearance returns to baseline over 1-2 weeks.
No pharmacokinetic studies in pregnancy; no dose adjustment recommended.
Oxy Contin is an extended-release formulation of oxycodone, indicated for around-the-clock pain management. Do not crush, chew, or break tablets, as this can lead to rapid release and fatal overdose. Use with caution in patients with respiratory compromise, head injury, or increased intracranial pressure. Monitor for signs of misuse, abuse, or addiction. Abrupt discontinuation may precipitate withdrawal; taper dose gradually. Constipation is common; consider prophylactic laxatives. Contraindicated in severe asthma, paralytic ileus, or hypersensitivity.
XDEMVY (lotilaner ophthalmic solution) 0.25% is the first FDA-approved treatment for Demodex blepharitis. Administer one drop in each affected eye twice daily (approximately 12 hours apart) for 6 weeks. Shake well before use. Contact lenses should be removed prior to instillation and may be reinserted 15 minutes after dosing. Avoid touching the dropper tip to any surface to prevent contamination.
Take Oxy Contin exactly as prescribed, usually every 12 hours. Do not take more or less than directed.,Swallow the tablet whole with water. Do not crush, chew, or break the tablet, as this can cause a dangerous overdose.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines, sedatives) as they increase the risk of severe sedation, respiratory depression, and death.,Do not stop taking Oxy Contin suddenly; ask your doctor how to safely discontinue the medication to avoid withdrawal symptoms.,Common side effects include constipation, nausea, drowsiness, and dizziness. Contact your doctor if you experience severe constipation, difficulty breathing, or signs of allergic reaction.,Store Oxy Contin in a secure place out of sight and reach of children and pets. Dispose of unused medication via a drug take-back program.,Do not drive or operate heavy machinery until you know how Oxy Contin affects you.,Inform all healthcare providers that you are taking Oxy Contin, especially before surgery or emergency treatment.
Use exactly as prescribed: one drop in each eye twice daily for 6 weeks.,Shake the bottle well before each use.,Remove contact lenses before applying and wait at least 15 minutes before reinserting.,Do not touch the dropper tip to your eye or any surface to avoid contamination.,If you miss a dose, apply as soon as you remember, but if it is close to the next dose, skip the missed dose and resume normal schedule.,Common side effects may include temporary stinging or blurred vision after application.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXYCONTIN vs XDEMVY, answered by our medical review team.
OXYCONTIN is a Opioid Analgesic that works by Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression.. XDEMVY is a Antiparasitic Agent that works by XDEMVY (lotilaner ophthalmic solution) is a gamma-aminobutyric acid (GABA)-gated chloride channel antagonist. It inhibits the GABA-gated chloride channels in Demodex mites, leading to paralysis and death of the mites.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXYCONTIN and XDEMVY depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXYCONTIN is: 10 mg orally every 12 hours; titrate based on pain severity and prior opioid exposure.. The standard adult dose of XDEMVY is: 1 drop in each eye once daily in the evening for 6 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXYCONTIN and XDEMVY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXYCONTIN is classified as Category C. FDA Pregnancy Category C prior to 2020; no adequate studies in pregnant women. First trimester: Limited data suggest possible increased risk of neural tube defects (1.8-fold) and o. XDEMVY is classified as Category C. No adequate and well-controlled studies in pregnant women. In animal reproduction studies, no teratogenic effects were observed at exposures up to 5 times the human exposure at the. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.